Business intelligence for bio/pharma drugs – DrugPatentWatch

Business intelligence for bio/pharma drugs – DrugPatentWatch, available at $44.99, has an average rating of 4.35, with 21 lectures, based on 99 reviews, and has 397 subscribers.

You will learn about Finding and evaluating generic drug market entry opportunities Branded drug lifecycle management Find generic drug entry opportunities Track drugs in development and explore new indications for existing drugs Study failed patent challenges to develop a better strategy Collect competitive intelligence by examining contractual disputes Track litigation to anticipate early generic entry Find and evaluate business opportunities Assess levels of generic competition Use drug price ranges to evaluate price elasticity Determine optimal prices before launch Evaluate buyer power with data on reimbursement segmentation Align distribution methods with information on where and how drugs are purchased Evaluate branded and generic market opportunities globally Anticipate 505(b)(2) and biosimilar approvals Strengthen new formulation patents by studying prior claims and litigation Adapt your gmp facility to capture changes in demand with brand erosion and generic launches as drug patents expire Position regulatory affairs to capture emerging opportunities Understand the roles of patents, trade secrets, trademark, and other forms of intellectual property protection in protecting branded pharmaceutical and biotechnology drugs Proactively adapt sourcing, purchasing, and supply chain management to anticipate changes in supply and demand with generic drug entry This course is ideal for individuals who are Generic pharmaceutical company portfolio managers or Branded drug lifecycle management, sourcing, procurement, and supply chain professionals or Pharmaceutical drug analysts, investment analysts, and patent analysts or Patent analysts or Patent Landscape Profilers or Biotech and Pharma Investors or Supply chain, sourcing, purchasing managers, procurement, wholesalers, distributors, and warehouses or Good Manufacturing Practice (GMP) facility owners and operators or Pharmaceutical regulatory affairs professionals, lawyers, consultants, and founders or Drug and medical device development managers It is particularly useful for Generic pharmaceutical company portfolio managers or Branded drug lifecycle management, sourcing, procurement, and supply chain professionals or Pharmaceutical drug analysts, investment analysts, and patent analysts or Patent analysts or Patent Landscape Profilers or Biotech and Pharma Investors or Supply chain, sourcing, purchasing managers, procurement, wholesalers, distributors, and warehouses or Good Manufacturing Practice (GMP) facility owners and operators or Pharmaceutical regulatory affairs professionals, lawyers, consultants, and founders or Drug and medical device development managers.

Enroll now: Business intelligence for bio/pharma drugs – DrugPatentWatch

Summary

Title: Business intelligence for bio/pharma drugs – DrugPatentWatch

Price: $44.99

Average Rating: 4.35

Number of Lectures: 21

Number of Published Lectures: 21

Number of Curriculum Items: 21

Number of Published Curriculum Objects: 21

Original Price: $199.99

Quality Status: approved

Status: Live

What You Will Learn

Finding and evaluating generic drug market entry opportunities
Branded drug lifecycle management
Find generic drug entry opportunities
Track drugs in development and explore new indications for existing drugs
Study failed patent challenges to develop a better strategy
Collect competitive intelligence by examining contractual disputes
Track litigation to anticipate early generic entry
Find and evaluate business opportunities
Assess levels of generic competition
Use drug price ranges to evaluate price elasticity
Determine optimal prices before launch
Evaluate buyer power with data on reimbursement segmentation
Align distribution methods with information on where and how drugs are purchased
Evaluate branded and generic market opportunities globally
Anticipate 505(b)(2) and biosimilar approvals
Strengthen new formulation patents by studying prior claims and litigation
Adapt your gmp facility to capture changes in demand with brand erosion and generic launches as drug patents expire
Position regulatory affairs to capture emerging opportunities
Understand the roles of patents, trade secrets, trademark, and other forms of intellectual property protection in protecting branded pharmaceutical and biotechnology drugs
Proactively adapt sourcing, purchasing, and supply chain management to anticipate changes in supply and demand with generic drug entry

Who Should Attend

Generic pharmaceutical company portfolio managers
Branded drug lifecycle management, sourcing, procurement, and supply chain professionals
Pharmaceutical drug analysts, investment analysts, and patent analysts
Patent analysts
Patent Landscape Profilers
Biotech and Pharma Investors
Supply chain, sourcing, purchasing managers, procurement, wholesalers, distributors, and warehouses
Good Manufacturing Practice (GMP) facility owners and operators
Pharmaceutical regulatory affairs professionals, lawyers, consultants, and founders
Drug and medical device development managers

Target Audiences

Generic pharmaceutical company portfolio managers
Branded drug lifecycle management, sourcing, procurement, and supply chain professionals
Pharmaceutical drug analysts, investment analysts, and patent analysts
Patent analysts
Patent Landscape Profilers
Biotech and Pharma Investors
Supply chain, sourcing, purchasing managers, procurement, wholesalers, distributors, and warehouses
Good Manufacturing Practice (GMP) facility owners and operators
Pharmaceutical regulatory affairs professionals, lawyers, consultants, and founders
Drug and medical device development managers

GET INSIGHTS INTO THE BIGGEST REVENUE-CHANGING EVENTS

By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.

Branded drug companies can experience precipitous revenue erosion as generic drugs rapidly gain market share. All the while patients, physicians, payers, pharmacists, and other healthcare stakeholders must race to keep up.

This course answers the following questions to help you adapt:

When will key drug patents expire?
How can I write stronger patents?
How can I defeat drug patents?
How can I find, evaluate, and plan for generic market entry opportunities?
How can I find proprietary out-of-court settlements and deal terms?

Comprehensive and actionable coverage of commercial, legal, and regulatory factors builds a solid foundation for strategic thinking. Diverse case studies build on this groundwork by analyzing and explaining real-work examples to form the underpinning for your tactical plans.

*INCLUDES FREE COMPANION TEXTBOOK

This course is the product of more than twenty years of providing guidance to drug development companies and other healthcare stakeholders.

Through developing the first website on the business of biotechnology in the 1990s (now owned by the New York Times), editing and publishing the Journal of Commercial Biotechnology, and leading data analytics for a subsidiary of Scientific American, I have had the fortune of spending considerable time at the bleeding edge of the commercial side of drug development.

The motivation to develop this course comes from my experiences running DrugPatentWatch, a comprehensive platform to help identify and evaluate opportunities around drug patent expiration and generic entry. In the early 2000s the first version of DrugPatentWatch was developed in response to repeated requests to answer the simple question: “When do drug patents expire?” As the platform matured, it became apparent that there was a strong need for a single source integrating broad strategic guidance to help stakeholders throughout the drug development and delivery value chain. This course was designed to meet that need.

As with my other publications, the focus of this course is on actionable intelligence. Because the legal and regulatory underpinnings of drug development and delivery are complex and change frequently, the approach taken by this course is to explain the current state of affairs and to provide representative examples to help you develop a deep understanding so you can quickly adapt to and capitalize on future events.

A primary objective of this course is to fill gaps in knowledge, helping you leverage your expertise, without being overly exhaustive. For readers seeking greater technical depth I provide links to some of the books and web-based resources that I found helpful.

Because strategic planning for branded drugs has many similarities to finding and prioritizing generic entry opportunities, this course has relevance for generic and branded companies alike. Likewise, distributors, payers, investors, and myriad other stakeholders will also benefit by understanding the commercial dynamics of pharmaceutical and biotechnology drugs.

I hope you enjoy this course as much as I did putting it together.

About the Author:

Yali Friedman, Ph.D. has more than 20 years experience providing business intelligence to life science companies. He was recently named one of the 100 most influential people in biotechnology by Scientific American. He is also author of the MBA-level textbook Building Biotechnology and publisher of the Journal of Commercial Biotechnology.

Course Curriculum

Chapter 1: Introduction

Lecture 1: Course Overview

Lecture 2: About your instructor

Lecture 3: About DrugPatentWatch

Lecture 4: Free companion text

Lecture 5: Disclaimer

Chapter 2: Innovative and Follower Drugs

Lecture 1: Small Molecule and Biologic Drugs – Biotechnology and Pharmaceutical Industry

Lecture 2: Generic Pharmaceutical vs Biosimilar Biotechnology Drugs

Lecture 3: Generic Pharmaceutical Drug Approval and Launch – Regulatory Affairs

Lecture 4: 505(b)(2) Drugs – Their impact on drug patents, and regulatory affairs

Chapter 3: Patents and Other Forms of Intellectual Property

Lecture 1: Patents and Other Forms of Intellectual Property

Lecture 2: Trade Secrets to Protect Drugs and Manufacturing Processes

Lecture 3: Trademarks to Protect Branded Drug Names

Chapter 4: Regulatory Exclusivity

Lecture 1: Regulatory Exclusivity and Government Approval of Drugs

Chapter 5: Analyzing patents and litigation

Lecture 1: Analyzing patents and litigation

Chapter 6: Market Size and Quality

Lecture 1: Making the Business Case – Market Size and Quality

Chapter 7: Branded Drug Launch and Lifecycle Management Strategies

Lecture 1: Drug Commercialization – Branded Drug Launch and Lifecycle Management Strategies

Chapter 8: Generic Portfolio Management

Lecture 1: Generic Portfolio Management – Prioritizing Generic Drug Launches

Chapter 9: Conclusion

Lecture 1: Conclusion

Chapter 10: Extra – Conference Presentations

Lecture 1: Finding And Evaluating Generic Drug Market Entry Opportunities for GMP & others

Lecture 2: Evaluating Innovative Portfolios and Preparing for Generic Entry

Lecture 3: Generic Portfolio Management, Partnering with Brands, and Staying Competitive

Instructors

Yali Friedman, Ph.D.
Publisher, DrugPatentWatch

Rating Distribution

1 stars: 1 votes
2 stars: 2 votes
3 stars: 16 votes
4 stars: 44 votes
5 stars: 36 votes

Frequently Asked Questions

How long do I have access to the course materials?

You can view and review the lecture materials indefinitely, like an on-demand channel.

Can I take my courses with me wherever I go?

Definitely! If you have an internet connection, courses on Udemy are available on any device at any time. If you don’t have an internet connection, some instructors also let their students download course lectures. That’s up to the instructor though, so make sure you get on their good side!

Menu